At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
DFTX Definium Therapeutics
Market Closed 10-16 16:00:00 EDT
32.10
-2.16
-6.30%
盘后32.02
-0.08-0.25%
19:40 EDT
High34.15Low32.02Vol1.94M
Open34.07D1 Closing34.26Amplitude6.22%
Mkt Cap4.31BTradable Cap4.17BTotal Shares134.37M
T/O62.99MT/O Rate1.49%Tradable Shares129.97M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Definium Therapeutics Issues Inducement Stock Options for 45,940 Shares to New Hires
Reuters  ·  10-14
Definium Therapeutics Issues Inducement Stock Options for 45,940 Shares to New Hires
Definium Therapeutics Initiated at Overweight by JP Morgan
Dow Jones  ·  10-10
Definium Therapeutics Initiated at Overweight by JP Morgan
U.S. Stocks on the MOVE-SpaceX, Humana, Delta Air Lines
Reuters  ·  10-09
U.S. Stocks on the MOVE-SpaceX, Humana, Delta Air Lines
JPMorgan Initiates Coverage on Definium Therapeutics With Overweight Rating, $84 Price Target
MT Newswires Live  ·  10-09
JPMorgan Initiates Coverage on Definium Therapeutics With Overweight Rating, $84 Price Target
Definium up as J.P.Morgan Starts with 'overweight' Rating on LSD-Based Therapy
Reuters  ·  10-09
Definium up as J.P.Morgan Starts with 'overweight' Rating on LSD-Based Therapy
Definium Therapeutics Shares up 4% Premarket After JP Morgan Initiates Coverage with Overweight Rating
THOMSON REUTERS  ·  10-09
Definium Therapeutics Shares up 4% Premarket After JP Morgan Initiates Coverage with Overweight Rating
Definium Therapeutics Inc : JP Morgan Initiates Coverage with Overweight Rating; Target Price $84
THOMSON REUTERS  ·  10-09
Definium Therapeutics Inc : JP Morgan Initiates Coverage with Overweight Rating; Target Price $84
Definium Therapeutics Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since January 2024
Dow Jones  ·  10-09
Definium Therapeutics Currently Down Eight Consecutive Days, on Pace for Longest Losing Streak Since January 2024
Analysts’ Top Healthcare Picks: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX)
TIPRANKS  ·  10-07
Analysts’ Top Healthcare Picks: ArriVent BioPharma, Inc. (AVBP), Definium Therapeutics (DFTX)
Definium Therapeutics Issues Inducement Stock Options for 334,810 Shares to New Hires
Reuters  ·  09-29
Definium Therapeutics Issues Inducement Stock Options for 334,810 Shares to New Hires
Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Definium Therapeutics (DFTX)
TIPRANKS  ·  09-19
Analysts Offer Insights on Healthcare Companies: Contineum Therapeutics, Inc. Class A (CTNM) and Definium Therapeutics (DFTX)
Definium Therapeutics Issues Inducement Stock Options to New Hires
TIPRANKS  ·  09-17
Definium Therapeutics Issues Inducement Stock Options to New Hires
Definium Therapeutics Logs Third Positive Phase 3 Readout for DT120 in Anxiety
TIPRANKS  ·  09-17
Definium Therapeutics Logs Third Positive Phase 3 Readout for DT120 in Anxiety
China's Lepu Biopharma H1 Revenue Rises 12.1% on Higher Drug Sales
Reuters  ·  09-16
China's Lepu Biopharma H1 Revenue Rises 12.1% on Higher Drug Sales
Stifel Nicolaus Reaffirms Their Buy Rating on Definium Therapeutics (DFTX)
TIPRANKS  ·  09-16
Stifel Nicolaus Reaffirms Their Buy Rating on Definium Therapeutics (DFTX)
Definium Therapeutics is Maintained at Buy by Canaccord Genuity
Dow Jones  ·  09-15
Definium Therapeutics is Maintained at Buy by Canaccord Genuity
U.S. Research Roundup-Eli Lilly, McDonald's, Welltower
Reuters  ·  09-15
U.S. Research Roundup-Eli Lilly, McDonald's, Welltower
UK's ImmuPharma Interim Net Loss Widens on Derivative Finance Loss
Reuters  ·  09-15
UK's ImmuPharma Interim Net Loss Widens on Derivative Finance Loss
UK's ValiRx Half-Year Loss Narrows, Cash Position Improves
Reuters  ·  09-15
UK's ValiRx Half-Year Loss Narrows, Cash Position Improves
Kestra Medical Technologies Q1 Revenue Beats Estimates, Raises FY Revenue Outlook
Reuters  ·  09-15
Kestra Medical Technologies Q1 Revenue Beats Estimates, Raises FY Revenue Outlook

Introduction

Company Name.
Definium Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company also develops MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. The company is headquartered in New York, New York.
Issue price:
--